Noah Wald-Dickler, MD, FACP, discusses the safety and efficacy of oral transition therapy, challenges in antimicrobial stewardship, and evidence-based alternatives presented at SHEA 2024.
Experts discuss the impact of elacestrant on patient well-being, including potential cardiovascular and gastrointestinal toxicities, quality of life, and patient feedback regarding access to treatment.